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A B S TR A CT
We study a mathematical model for the human immunodeﬁciency virus (HIV) and hepatites C virus (HCV) coinfection. The model predicts four distinct equilibria: the 
disease free, the HIV endemic, the HCV endemic, and the full endemic equilibria. The local and global stability of the disease free equilibrium was calculated for the full 
model and the HIV and HCV submodels. We present numerical simulations of the full model where the distinct equilibria can be observed. We show simulations of the 
qualitative changes of the dynamical behavior of the full model for variation of relevant parameters. From the results of the model, we infer possible measures that could 
be implemented in order to reduce the number of infected individuals. 
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1. Introduction 
 
HIV appears frequently associated with other diseases, such as 
tuberculosis (Naresh and Tripath, 2005) or hepatitis viruses 
(Maidana et al., 2005). 
Throughout the world, 34–46 million people are infected with HIV, 
of which 4–5 millions are coinfected with HCV (Wolff et al., 2008). In 
the USA, 360,000 people are coinfected with HIV and HCV. Additionaly, 
1.2 million are solely infected with HIV and more than 4 million are solely 
infected with HCV (Franciscus,   2012). 
Worldwide, there are 150 million cases of chronic HCV carri- ers, 
and it is known that 85% of those with HCV exposure develop chronic 
infection (Hoofnagle, 1997; National, 1997). Chronic infec- tion results 
in a large number of deaths annualy due to cirrhosis and hepatocellular 
carcinoma. Moreover, liver transplants, for HCV induced liver disease 
patients, are a major part of health care costs (EASL, 1999). 
HIV and HCV share the same transmission routes, namely by 
injection drug use, sexual contact, mother to child transmission during 
pregnancy or birth, blood and blood products transfusion, organs 
transplantation from infected donors, exposure to blood by health care 
professionals (Alter, 2006; Sulkowski, 2008). 
Coinfection adds more severity for the two diseases involved. HIV 
accelerates the progression of HCV in dually infected patients. 
 
 
 
Having a count of CD4+ T cells below 200 cells/mm3 increases the 
risk of severe liver disease (GAT, 2009). Moreover, there is a higher 
risk of cirrhosis, end-stage liver disease, hepatocarci- noma, and 
hepatic-related death (Thein et al., 2008; Departamento, 2011). 
The current international consensus, to control the HIV epi- demic, 
focuses on the need for clear leadership on policies and programs for 
prevention, early diagnosis, treatment that respects human rights, and 
quality of health care, effective and accessible to everyone. In what 
concerns coinfection, some successful treat- ments for HCV using drug 
combination in individuals coinfected with HIV have been reported. 
Furthermore, most people with HCV can be treated successfully for 
HIV (Franciscus, 2012). However, more studies are needed to show the 
efﬁcacy of new antiviral drugs for HCV in people coinfected with HIV. 
In the last few decades, mathematical models have been applied in the 
literature to the modeling of infectious diseases. HIV and known 
coinfections epidemiologies are the research topic of some of those 
models. In Vickerman et al. (2008), the authors proposed a transmission 
model for HCV/HIV coinfection, aimed at evaluating the cost-
effectiveness of needle and syringe programs for injecting drug users 
(IDUs). They concluded that although the needle/syringe sharing events 
were deﬁned as low risk in Rawalpindi, the preva- lence of HIV/HCV in 
IDUs would increase. They emphasized the importance of intervention 
measures in that low prevalence set- ting, in order to prevent the 
HIV/HCV prevalence. Recently, in Vickerman et al. (2012), the 
authors used a mathematical model to understand the trends in the 
prevalence of HIV and HCV. They determined the different 
epidemiological proﬁles and how these 
 
. 
  
 
 
 
Fig. 1. Flow chart of the model. 
 
proﬁles affect intervention impact. They concluded that there were 
threshold levels of HCV prevalence below which HIV risk was negli- gible. 
Nevetheless, these thresholds varied by setting. The authors infered that 
HIV and HCV prevalence settings could provide new insights into IDU 
risk behaviour and intervention  impact.  In de Vos et al. (2012), the 
authors proved that HCV prevalence could be used as an indicator of risk 
for successful HIV infection, in an IDU population. In Waziri et al. 
(2012), the authors formulated a mathe- matical model for HIV/AIDS 
treatment, where vertical transmission from mother to child was 
included. It is shown that highly active antiretroviral therapy (HAART) 
and control of vertical transmission rate were associated with a reduction 
of the HIV transmission. In Bhunu and Mushayabasa (2013), the authors 
studied a mathemat- ical model for HIV and HCV coinfection, that 
includes treatment for boh diseases. The model predicted that HCV had 
an ongoing prolonged negative effect on the population health, 
irrespective of their HIV status. The authors infered that speciﬁc measures 
to con- trol HCV should be taken/reinforced in resource limited settings. 
In 2013, Corson et al. (2013) proposed a mathematical model to 
explore the risk of HCV infection through the sharing of injecting 
paraphernalia (including ﬁlters, cookers and water). Namely, the 
sharing of injecting paraphernalia among IDUs is common, thus, HCV 
transmission through this route could contribute to the grow- ing burden 
in healthcare systems associated with it. The authors infered that more 
work was needed to detail the contribution of the paraphernalia 
sharing to the spread of HCV, and that health care providers should 
distribute sterile paraphernalia to prevent HCV infection. 
In this paper, we study a mathematical model for HIV and HCV 
coinfection. The novelty of the model is in the inclusion of treat- ment 
for both diseases and of vertical transmission from mother to child, in 
the case of HIV, in one model. We are aware of HIV and HCV sharing 
several transmission routes, nevertheless, here we only consider sexual 
transmission for HIV and HCV and vertical transmission for HIV. 
Bearing this in mind, the paper is organized as follows. The 
model is studied in Section 2. In Sections 2.2–2.3, we compute the 
reproduction numbers and the local and global stability of the dis- ease 
free equilibria. In Section 2.4, we present several bifurcation diagrams 
that reveal the dynamical behavior of the model for vari- ation of 
relevant parameters. Simulation results of the full model are presented 
in Section 3. Section 4 concludes this study and sheds some light on 
possible future research directions. 
 
 
 
2. The HIV and HCV coinfection model 
 
In this section, we describe the HIV and HCV coinfection model. We 
compute the reproduction numbers of the full model, and of the two 
submodels (HIV only and HCV only models). We study the local stability 
of the disease free equilibria for the full model and the global. We 
compute the sensitivity indices of the reproduction number to relevant 
parameters of the model. We present bifurca- tion diagrams, built with 
the help of XPPAUT, to better understand the dynamics of the proposed  
model. 
  
2.1. Description of the model 
 
The population of the model includes nine classes, namely, the 
susceptible individuals, S, the individuals infected with HIV, Ia, the 
individuals showing symptoms of AIDS, Aa, the individuals infected with 
HCV, Ic, the individuals infected with chronic HCV, Cc, the 
individuals coinfected with HIV and HCV, IaIc, the individuals coin- fected 
with HIV and with chronic HCV, IaCc, the individuals showing symptoms 
of AIDS and coinfected with HCV, AaIc, and the individ- uals showing 
symptoms of AIDS and with chronic HCV coinfection, AaCc. 
In Fig. 1, it is presented the ﬂow chart of the model. It repre- sents 
schematically the epidemiology of HIV and HCV coinfection. The 
different disease stages are reproduced by the different com- partments 
(rectangles) and the arrows indicate the way individuals progress from 
one stage to the other. 
At time t, the population of size N(t), has constant inﬂow of 
susceptible individuals, S, at a rate A. For all classes, the natural 
mortality rate is µ. Susceptible individuals, S, exposed to HIV, move to 
class Ia, at a rate AH, given by: 
 
 
 
Parameter bh is the effective sexual contact rate for HIV infection to 
occur, and c is the average number of sexual partners per unit of time. 
On the other hand, when in contact with HCV patients, susceptible 
individuals, S, move to class Ic, at a rate: 
  
Table 1 
Description of the variables and the parameters of model (1). 
Variable/Parameter Description 
S Susceptible individuals 
Ia Individuals infected with HIV 
Aa Individuals showing symptoms of AIDS 
Ic Individuals infected with HCV 
Cc Individuals infected with chronic  HCV 
Ia Ic Individuals coinfected with HIV and HCV 
Ia Cc Individuals coinfected with HIV and chronic HCV 
Aa Ic Individuals showing symptoms of AIDS and with HCV 
coinfection 
Aa Cc Individuals showing symptoms of AIDS and  with 
chronic HCV coinfection 
A Recruitment rate 
µ Natural mortality rate 
c Average number of sexual partners 
bh Effective sexual contact rate for HIV transmission to 
occur 
bc Effective sexual contact rate for HCV transmission to 
occur 
a3 Modiﬁcation parameter 
77i , = 1, 2 Modiﬁcation parameter 
ri i = 1, 2, 3 HCV treatment rates 
pi , i = 1, 2, 3 Proportion of infected individuals who are chronic 
carries 
dc Mortality due to HCV 
E Fraction of newborns infected with HIV that   die 
immediately  after  birth 
e Rate of newborns infected with HIV 
p Rate of progression to AIDS 
vi , i = 1, 2, 3 HIV treatment rate 
da Mortality due to HIV 
a Modiﬁcation parameter 
ı Modiﬁcation parameter 
where  parameter  bc   is  the  effective  contact  rate  for  HCV  infec- tion 
to occur. Parameters 771, 772, a3 > 1 model the fact that dually infected 
individuals are more infectious than their corresponding 
  1   
aC 
Average time that an individual infected with HCV 
remains in a state of acute    infection 
counterparts. 
A fraction of newborns are infected with HIV during birth and hence 
are directly recruited into the infectious class, Ia, at a rate (1 − E)e. 
Other children die at birth (0 ≤ E ≤ 1), where E is the frac- tion of 
newborns infected with HIV that die immediately after birth, and e is the 
rate of newborns infected with HIV. The individuals infected with HIV, 
Ia, move at a rate p to the AIDS class, Aa. Indi- viduals showing 
symptoms of AIDS are treated at a rate v1, and die because of AIDS at a 
rate da. 
The individuals infected with HCV, Ic move to the susceptible 
class, S, after treatment at a rate r1. They can progress to a chronic 
stage, Cc, at a rate p1aC, where p1 is the proportion of infected indi- 
viduals who are chronic carriers and 1/aC is the average time that an individual infected with HCV remains in a state of acute infec- 
Individuals showing symptoms of AIDS, Aa, are infected with HCV 
at a rate aAC and move to class AaIc. The individuals in class AaIc are 
treated and recover from HCV infection at a rate r3 and move to class Aa or 
are treated and recover from AIDS stage at a rate v2 and move to class 
IaIc. The individuals in class AaIc become HCV chronic carriers at a 
rate p3aC and move to class AaCc. Parameter p3 is the proportion of 
individuals in AaIc class who are chronic carriers. Individuals showing 
symptoms of AIDS and with chronic HCV coinfection, AaCc, are treated 
for HIV at a rate v3, and move to IaCc. 
The following nonlinear system of ordinary differential equa- tions 
summarizes the description of the model: 
tion. The individuals with chronic HCV infection, Cc, die because of 
HCV at a rate dc. 
 
 
We now deﬁne the dynamics of the coinfection. The individ- uals 
infected with HIV, Ia, are infected with HCV at a rate aAC and move to 
class IaIc. Modiﬁcation parameter a > 1 accounts for the fact that there is 
an increased risk of getting HCV for someone already infected with 
HIV, due to the vulnerability of the immune system. Reciprocally, the 
individuals infected with HCV, Ic are infected with HIV at a rate ıAH and 
move to the class IaIc. Parameter ı > 1 accounts for the increased 
susceptibility to HIV infection for HCV infected people, since HCV 
accelerates the decline of the immune function. Dually infected 
individuals, IaIc, recover from HCV infection at a rate r2 and move to 
class Ia. On the other hand, they can progress to AIDS at a rate p and 
move to class AaIc. Moreover, IaIc individ- 
uals may become HCV chronic carriers, at a rate p2aC, and move to 
 
 
 
 
 
 
 
 
class IaCc. Parameter p2 is the proportion of dually infected individ-  
uals who are chronic carriers. Dually HIV and chronic HCV infected  
individuals, IaCc, may progress to AIDS at a rate p and move to class 
AaCc. 
  
  
 
 
 
Fig. 2. Sketch of the bifurcation diagram of model (1), for different values of bh , the 
effective sexual contact rate for a HIV infection to occur. Remaining parameter values are 
given in Table 2. Green: stable disease free equilibrium, red: stable HIV endemic 
equilibrium. For more information, see text. (For interpretation of the references to color 
in this ﬁgure legend, the reader is referred to the web version of this article.) 
 
 
 
Fig. 3. Schematic bifurcation diagram of model (1), for different values of bc , the 
effective contact rate for HCV infection to occur. Remaining parameter values are given 
in Table 2. Green: stable disease free equilibrium, orange: stable HCV endemic equilibrium. 
For more information, see text. (For interpretation of the references to color in this ﬁgure 
legend, the reader is referred to the web version of this article.) 
 
 
 
Fig. 4. Sketch of the bifurcation diagram of model (1), for different values of c, the average 
number of sexual partners. Remaining parameter values are given in Table 2. Green: stable 
disease free equilibrium, red: stable HIV endemic equilibrium, black: stable full endemic 
equilibrium. For more information, see text. (For interpretation of the references to color 
in this ﬁgure legend, the reader is referred to the web version of this article.) 
 
Fig. 5. Sketch of the bifurcation diagram of model (1), for different values of e, the fraction 
of newborns infected with HIV during birth. Remaining parameter values are given in 
Table 2. Red: stable HIV endemic equilibrium, green: stable disease free equilibrium. For 
more information, see text. (For interpretation of the references to color in this ﬁgure 
legend, the reader is referred to the web version of this article.) 
 
 
 
Fig. 6. Bifurcation diagram of model (1), for different values of r1 , the treatment rate for 
individuals solely infected with HCV. Remaining parameter values are given in Table 2, 
except for bc = 0.5. Orange: stable HCV endemic equilibrium, green: stable disease free 
equilibrium. For more information, see text. (For interpretation of the references to color 
in this ﬁgure legend, the reader is referred to the web version of this article.) 
 
 
 
Fig. 7. Sketch of the bifurcation diagram of model (1), for different values of r2 , the 
treatment rate for HCV of individuals dually infected with HIV and HCV. Remaining 
parameter values are given in Table 2, except for bh = 0.15, bc = 0.5 and aC = 0.43. 
Black: stable two disease endemic equilibrium, red: stable HIV endemic equilibrium. For 
more information, see text. (For interpretation of the references to color in this ﬁgure 
legend, the reader is referred to the web version of this article.) 
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Fig. 8. Disease free equilibrium of system (1) for parameter values given in Table 2 and initial conditions (RHIV = 0.1813, RHCV = 0.7895, R0 = 0.7895). Remaining variables tend asymptotically 
to zero. 
 
  
We start by computing the reproduction number of the sys- tem (2), 
RHIV. We use the next generation method (Driessche and Watmough, 
2002). 
 
 
 
In Table 1, we summarize the parameters and the variables of 
  
model (1). 
 
2.2. Reproduction numbers and stability of disease free equilibria 
 
 
 
In this subsection, we compute the reproduction number of model 
(1), R0. The basic reproduction number is deﬁned as the num- ber of 
secondary infections due to a single infection in a completely susceptible 
population (Driessche and Watmough, 2002). 
We begin by considering two sub-models of model (1). Model 
(2) is obtained from model (1) by setting the variables concerning HCV 
dynamics (Ic, Cc, IaIc, IaCc, AaIc and AaCc) to zero, and model 
(4) follows from model (1) by setting the variables concerning HIV 
dynamics (Ia, Aa, IaIc, IaCc, AaIc and AaCc) to zero. 
 
The disease free equilibrium of model (2) is given by: 
    
 
 
 
Using the notation in Driessche and Watmough (2002) on sys- tem (2), 
matrices for the new infection terms, F, and the otherterms, 
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Fig. 9. Stable endemic HIV equilibrium of system (1) for given parameter values in Table 2, except bh = 0.1, and initial conditions (RHIV = 2.1930, RHCV = 0.1813, R0 = 2.1930). Remaining 
variables go asymptotically to zero. 
 
 
V, are given by: 
We proceed with the computation of the reproduction number of 
submodel (4) below, RHCV. 
   
 
 
The associative basic reproduction number is given by: The disease free equilibrium state P
2 of model (4) is given by: 
 
 
  
where p indicates the spectral radius of FV−1. By Theorem 2 in 
Driessche and Watmough (2002), we obtain the following lemma. 
Using the notation in Driessche and Watmough (2002) on sys- tem 
(4), matrices for the new infection terms, F, and the other terms, V, are 
given by: 
 
Lemma 1.   The disease free equilibrium P1  is locally   asymptotically  
stable if RHIV <1 and unstable if RHIV > 1. 
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Fig. 10. Stable HCV endemic equilibrium of system (1) for parameter values given in Table 2, except bc = 0.5, and initial conditions (RHIV = 0.7895, RHCV = 1.8129, R0 = 1.8129). Remaining 
variables tend asymptotically to zero. 
 
 
  
Using the notation in Driessche and Watmough (2002) on sys- tem 
(1), matrices for the new infection terms, F, and thee other terms, V, 
are given by: 
The associative basic reproduction number is given by:  
 
 
 
 
where p indicates the spectral radius of FV−1. By Theorem 2 in 
Driessche and Watmough (2002), we obtain the following result.  
Lemma 2.   The disease free equilibrium P2  is locally   asymptotically  
⎜ ⎟
 
stable if RHCV  <1 and unstable if RHCV  > 1.⎜  
We now continue with the calculation of the reproduction num- 
ber  of  the  full  model (1),  R0. The  disease  free  equilibrium  state, P0, 
 
 
of model (1) is given  by:  
⎜⎟
 
 ⎟ 
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Fig. 11. Stable two disease endemic equilibrium of system (1) for given parameter values in Table 2, except for bh = 0.15, aC = 0.43 and bc = 0.5, and initial conditions (RHIV = 3.2895, 
RHCV = 1.7764, R0 = 3.2895). 
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Fig. 12. Dynamics of the relevant variables of system (1) for different values of bh , the effective sexual contact rate for HIV transmission to occur, for given parameter values in Table 2 and 
initial conditions. For more information, see text. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The associative basic reproduction number is computed to be: 
 
  
 
whe
re p indicates the spectral radius of FV−1. By Theorem 2 Driessche and 
Watmough (2002), we derive the following lemma. 
 
Lemma 3. The disease free equilibrium P0 is locally asymptotically 
stable if R0 <1 and unstable if R0 > 1. 
 
2.3. Global stability of the disease free equilibria 
 
In this section, we compute the global stability of the disease free 
equilibrium of the full model (1). We begin by calculating the stability 
of the disease free equilibria of the two submodels (2) and (4). 
Lemma 4. For model (2), the disease free equilibrium P1 is globally 
asymptotically stable if RHIV  <  1. 
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Fig. 13. Dynamics of the relevant variables of system (1) for different values of bc , the effective contact rate for HCV infection to occur. Parameter values are in Table 2 and initial conditions in 
the text. For more information, see text. 
 
Proof.  We use the comparison theorem to prove the global sta- 0) as t→∞ for RHIV < 1, so that P
1 is globally asymptotically stable 
bility of the disease free equilibrium of submodel (2). The rate of 
change of the variables (Ia, Aa) of system (2) can be rewritten as 
follows. 
if RHIV < 1. D 
We now repeat the same procedure for the computation of the global 
stability of the disease free equilibrium of submodel (4). 
a˙
 
 
  
  
 
 
 
 Lemma 5.   For the submodel (4), the disease free equilibrium P2 is 
   globally asymptotically stable if RHCV < 1. 
where F and V are as deﬁned above for system (2). Since S ≤ N 
for all t ≥ 0, then: 
Proof. We use a comparison theorem to prove the global sta- bility of 
the disease free equilibrium of submodel (4). The rate of change of 
the variables (Ic, Cc) of system (4) can be rewritten 
  
 
 
 
as: 
 
  
 
 
 
If RHIV < 1, then p(FV
−1) < 1, which is equivalent to say that the 
matrix F − V  has all eigenvalues in the left-half plane (Driessche 
 
 
 
and Watmough, 2002). It follows that the linear system given by 
equality (9) is stable whenever RHIV  < 1, and hence (Ia(t), Aa(t)) → (0, 
where F and V are as deﬁned above for system (4). Since S ≤ N 
for all t ≥ 0, then: 
0) as t→∞ for this linear ordinary differential equation (ODE) 
system. Consequently, after using a standard  comparison  theo- rem 
(Lakshmikantham et al., 1989; Smith and Waltman, 1995), we obtain 
(Ia(t), Aa(t)) → (0, 0), for the nonlinear system given by the 
 
 
last two equations of system (2). Returning now to the ﬁrst equation of model (2) and substituting Ia = Aa = 0 in this equation, we obtain a linear 
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system with S(t) → A/µ. Thus, (S(t), Ia(t), Aa(t)) → (A/µ, 0, If RHCV < 1, then p(FV
−1) < 1, which is equivalent to say that the 
matrix F − V has all eigenvalues in the left-half plane (Driessche and  
Watmough,  2002).  It  follows  that  the  linear  system    given 
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Fig. 14. Dynamics of the relevant variables of system (1) for different values of c, the average number of sexual partners per unit of time, for given parameter values in Table 2 and initial 
conditions. For more information, see text. 
 
 
by the equality (11) is stable whenever RHCV < 1, and hence (Ic(t), 
Cc(t)) → (0, 0) as t→ ∞ for this linear ODE system. Consequently, 
after using a standard comparison theorem (Lakshmikantham et al., 1989; 
Smith and Waltman, 1995), we obtain (Ic(t), Cc(t)) → (0, 0) for  the  
nonlinear  system,  given  by  the  last  two  equations  of  (4). Returning 
now to the ﬁrst equation of submodel (4) and substitut- ing Ic = Cc = 0 in 
this equation gives a linear system with S(t) → A/µ. Thus, (S(t), Ic(t), 
Cc(t)) → (A/µ, 0, 0) as t→ ∞ for RHCV < 1, so that P
2 is globally 
asymptotically stable if RHCV < 1. D 
The global stability of the disease free equilibrium of model (1), can 
only be achieved in very speciﬁc conditions, namely, when new 
coinfection cases are prevented from occurring. Patients infected with HIV 
or HCV could not become coinfected in such conditions. We feel that this 
condition is somewhat unrealistic and do not include it here. New 
techniques will be applied in future work in order to try to prove the 
global stability of the disease free equilib- rium. 
 
2.4. Bifurcation analysis of the model 
 
In this section, we use XPPAUT (Ermentrout, 2006) to draw 
schematic bifurcation diagrams for six relevant parameters of the 
model (1). Changing colors indicates a change in the stability of the 
equilibria. 
Fig. 2 is a sketch of the bifurcation diagram of model (1) for the 
variation of parameter bh, the effective sexual contact rate for a HIV 
infection to occur. We start from a disease free equilibrium and increase 
bh. At bh = 0.0456, there is a bifurcation point (1), at which the model 
bifurcates to the stable HIV endemic equilibrium. The color green means 
that the disease free equilibrium is stable and the color red means that it 
has lost stability, and now is the HIV endemic equilibrium that it is stable. 
Thus, increasing the effective sexual contact rate for HIV infection to 
occur will translate in new cases of HIV infections. 
Fig. 3 depicts the sketch of the bifurcation diagram of model (1), for 
different values of bc, the effective contact rate for HCV infec- tion to 
occur. We start from a stable disease free equilibrium and increase bc. 
At bc = 0.2758, there is a bifurcation point (1), where the model 
bifurcates to the stable HCV endemic equilibrium. This means that 
increasing the effective contact rate for HCV infection to occur will 
promote the appearance of new cases of  HCV. 
In Fig. 4 we plot a sketch of the bifurcation diagram of model (1), for 
variation of parameter c, the average number of sexual partners. We start 
from a disease free equilibrium and increase c. At c = 1.267, there is a 
bifurcation point (1), at which the model bifurcates to the 
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Fig. 15. Dynamics of the relevant variables of system (1) for different values of e, the fraction of newborns infected with HIV during birth, for given parameter values in Table 2, except for bh 
= 0.1, and initial conditions. For more information, see text. 
 
 
stable HIV endemic equilibrium. This means that increasing the 
average number of sexual partners of susceptible individuals will, as 
expected, translate in new cases of HIV infections. Increasing further 
c, a secondary bifurcation occurs at c = 8.651 (2), at which the model 
changes the dynamical behavior to a stable full endemic equilibrium. 
Biologically this implies that increasing the average number of sexual 
partners will burst coinfection cases. Note that as both diseases, HIV 
and HCV share the same transmission route, in this case, by sexual 
contact, increasing the average number of sexual partners affects both 
diseases. Moreover, as HCV is more difﬁcult to be transmitted through 
sexual intercourse, it is reason- able that for HCV to occur a larger 
number of sexual partners is needed. 
In Fig. 5 we depict a schematic bifurcation diagram of model (1), for 
different values of e, the fraction of newborns infected with HIV during 
birth. We start from a stable HIV endemic equilibrium and decrease e. At 
e = 0.0084 there is a bifurcation point (1), at which the model bifurcates 
to the stable disease free equilibrium. The model predicts, in this case, 
that decreasing the number of infected newborns will decrease the number 
of HIV infected  individuals. 
Fig. 6 shows the sketch of the bifurcation diagram for differ- ent 
values of r1, the treatment rate for individuals solely infected with 
HCV. We start from a a stable HCV endemic equilibrium and increase r1. 
At r1 = 0.5277, there is a bifurcation point (1), at which the model 
bifurcates to the disease free equilibrium. This means that  increasing  
the  treatment  rate  for  individuals  solely infected 
 
with HCV is a successful strategy, since patients recover from HCV 
infection. 
In Fig. 7 we draw a schematic bifurcation diagram of model (1), for 
different values of r2, the treatment rate for HCV, of individ- uals 
dually infected with HIV and HCV. We start from a stable two disease 
endemic equilibrium. At r2 = 0.4203 there is a bifurcation point (1), at 
which the model bifurcates to the stable HIV endemic equilibrium. 
Biologically, this means that increasing the treatment rate for HCV of 
individuals dually infected with HIV and HCV leads to a recovery from the 
HCV infection. The individual returns to the stage of HIV solely infection. 
In the next section we will present numerical simulations where 
bifurcation between distinct equilibria can be observed, for varia- tion 
of the parameters considered above. 
 
 
3. Numerical results 
 
We present the numerical simulations of model (1). The param- eter 
values used in the simulations can be found in Table 2 and the following 
initial conditions S(0) = 500, Ia(0)= 10= IaIc(0), Aa(0)= 5, Cc(0)= 5, 
Ic(0) = 15, IaCc(0) = 10, AaIc(0)= 3, AaCc(0) = 1 are used. 
In Fig. 8, we plot the dynamics of the relevant variables of system (1). 
We observe that, for the given parameter values and initial 
conditions, the model approaches asymptotically the stable disease free 
equilibrium. 
  =0.1 
  =0.001 
S
u
s
c
e
p
ti
b
le
 p
o
p
u
la
ti
o
n
 
In
d
iv
id
u
a
ls
 s
h
o
w
in
g
 s
y
m
p
to
m
s
 o
f 
A
ID
S
 
In
d
iv
id
u
a
ls
 i
n
fe
c
te
d
 w
it
h
 c
h
ro
n
ic
 H
C
V
 
600 14 
 
  r1=0.25 
  r1=0.7 
  r1=0.25 
  r1=0.7 
In
d
iv
id
u
a
ls
 i
n
fe
c
te
d
 w
it
h
 H
C
V
 
  r1=0.25 
  r1=0.7 12
 
500 
10 
400 
 
8 
300 
6 
 
200 
4 
 
100 2 
 
0 
0 100 200 300 400 500 600 
Time 
0 
0 100 200 300 400 500 600 
Time 
 
5 
 
4.5 
 
4 
 
3.5 
 
3 
160 
 
140 
 
120 
 
100 
 
2.5 80 
 
2 
60 
1.5 
40 
1 
0.5 
20
 
 
0 
 
40 
 
35 
 
30 
 
25 
 
20 
 
15 
 
10 
 
5 
 
0 
0 100 200 300 400 500 600 
Time 
 
Fig. 16. Dynamics of the relevant variables of system (1) for different values of r1 , the treatment rate for individuals solely infected with HCV, for given parameter values in Table 2, except for 
bc = 0.5, and initial conditions. For more information, see text. 
 
 
 
In Fig. 9, we observe that the model approaches asymptotically the 
stable endemic HIV equilibrium. 
Fig. 10 shows the stable endemic HCV equilibrium for system (1). 
In Fig. 11, we depict the dynamics of the variables of system (1). 
We observe that, for the given parameter values and initial 
conditions, the model approaches asymptotically the stable two 
disease endemic equilibrium. 
Fig. 12 shows the dynamics of the variables of system (1) for 
different values of bh, the effective contact rate for HIV infection to 
occur. We observe that as bh increases  the  system  (1)  bifur- cates from 
the stable disease free equilibrium to the stable HIV endemic 
equilibrium. Realistically, augmenting the sexual contact rate between 
individuals is followed by a burst of HIV  infection. 
In Fig. 13, it is shown the dynamics of the variables of system (1) for 
different values of bc, the effective contact rate for HCV infection to occur. 
We observe that as bc increases the system (1) bifurcates from the stable 
disease free equilibrium to the stable HCV endemic equilibrium. This 
behavior translates, biologically, in new cases of HCV for higher values of 
bc. 
Fig. 14 depicts the behavior of system (1) for different values of c, the 
average number of sexual partners per unit of time. We observe 
that as c increases the system (1) bifurcates from the stable disease free 
equilibrium to the stable HIV endemic equilibrium and then, increasing 
further the value of c, there is another bifurcation to the full endemic 
equilibrium. Biologically, this means that augmenting the average 
number of sexual partners fuels the appearance of new cases of HIV 
infection, and, after some value, it even promotes the appearance of 
coinfection cases. 
In Fig. 15 are depicted the dynamics of the variables of system 
(1) for different values of of e, the fraction of newborns infected with 
HIV during birth. We observe that as e increases the system 
(1) bifurcates from the stable disease free equilibrium to the stable HIV 
endemic equilibrium. 
In Fig. 16 we plot the behavior of system (1) for different val- ues 
of r1, the treatment rate for individuals solely infected with HCV. We 
observe that as r1 increases the stable HCV endemic state gives rise to the 
stable disease free equilibrium. This means that the treatment was 
successful and patients recovered from  HCV. 
In Fig. 17 we can observe the effects on the dynamics of model (1), 
for variation of r2, the treatment rate for individuals dually infected 
with HIV and HCV. As r2 increases the system (1) bifur- cates from 
the stable full endemic equilibrium to the stable HIV endemic 
equilibrium. Thus, patients recover from HCV  infection. 
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Fig. 17. Dynamics of the relevant variables of system (1) for different values of r2 , the treatment rate for HCV in individuals dually infected with HIV and HCV, for given parameter values in 
Table 2, except for bh = 0.15, bc = 0.5, and aC = 0.43, and initial conditions. For more information, see text. 
 
Table 2 
Parameters used in the numerical simulations of model (1). Where appropriate the units are 
year−1 . 
 
 
Parameter Value Reference 
 
 
c 1 Estimated 
bh 0.036 Hollingsworth et al. (2008) 
a3 1.0002 Estimated 
bc 0.05 van de Laar et al. (2010) 
771 1.0002 Bhunu and Mushayabasa (2013) 
772 1.002 Estimated 
A 12 Estimated 
µ 0.02 Bhunu and Mushayabasa (2013) 
r1 0.25 Bhunu and Mushayabasa (2013) 
r2 0.2 Estimated 
r3 0.15 Estimated 
p 0.1908 Nyabadza and Mukandavire (2011) 
a 1.001 Bhunu and Mushayabasa (2013) 
E 0.2 Waziri et al. (2012) 
e 0.1 Estimated 
v1 0.2 Bhunu and Mushayabasa (2013) 
v2 0.2 Estimated 
v3 0.15 Estimated 
da 0.33 Bhunu and Mushayabasa (2013) 
dc 0.2801 Bhunu and Mushayabasa (2013) 
ı 1.001 Bhunu and Mushayabasa (2013) 
p1 0.43 Sanchez et al. (2013) 
p2 0.45 Estimated 
p3 0.47 Estimated 
    a C 0.1667 Sanchez et al.  (2013)   
4. Conclusion 
 
In this paper, we analyzed a mathematical model for the coinfec- tion 
of HIV and HCV, that includes treatment for both diseases, and vertical 
transmission in the case of HIV. We studied the local sta- bility of the 
disease free equilibria for the full model and the global stability of the 
disease free equilibria for the two submodels (HCV only and HIV only 
submodels). XPPAUT was used to sketch bifur- cation diagrams, for 
relevant parameters, e.g., the mean number of sexual partners, the sexual 
contact rates, and the treatment rates. Numerical results illustrate the 
change on the dynamical behavior of the model for these parameters. The 
outcomes suggest that spe- ciﬁc measures should be considered, by the 
policy makers, in order to reduce HIV infection, such as: distributing more 
condoms to indi- viduals; develop campaigns in order to warn individuals 
about the consequences of having many sexual partners; continuing 
treat- ment for AIDS and pursuing the investigation of new and better 
drugs to combat HIV, treat newborns infected with HIV and advise 
pregnant women for the beneﬁts of HIV treatment. Considering HCV 
infection, treatment is highly recommended as well as other measures 
(e.g., more informational campaigns about the disease, its transmission 
routes, amongst others) in order to decrease the num- ber of infectious and 
of chronic carriers. Future work will focus on the study of regular 
screening for HIV and of condom use, of the effects of needle sharing, 
as well as an application/validation of the 
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model to real portuguese data, with corresponding estimation of 
parameter values. 
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